Outlook Therapeutics Competitors and Similar CompaniesClear all

Outlook Therapeutics's competitors and similar companies include Janssen, Chugai Pharmaceutical, Epizyme and Loxo Oncology.

	Outlook Therapeutics Outlook Therapeutics (formerly Oncobiologics) is a clinical stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics.	Janssen Janssen is a company providing prescription pharmaceutical products.	Chugai Pharmaceutical Chugai Pharmaceutical is a pharmaceutical company specializing in the fields of oncology, as well as bone, joint, and renal diseases.	Epizyme Epizyme is a clinical stage biopharmaceutical company focusing on treatments for blood cancer and tumors.	Loxo Oncology Loxo Oncology is a biopharmaceutical company focused on targeted cancer therapies for genetically-defined patient populations.
Founding Date	Founding Date 2011	Founding Date 1953	Founding Date 1925	Founding Date 2007	Founding Date 2013
Type	Type Public	Type Subsidiary	Type Public	Type Public	Type Subsidiary
Tags	Tags Healthcare biotech oncology pharma	Tags Healthcare biotech oncology pharma	Tags Healthcare biotech oncology pharma	Tags Healthcare biotech oncology pharma	Tags Healthcare biotech oncology pharma
Locations	Locations Woodbridge Township, US HQ	Locations Raritan, US HQ Vienna, AT Prague, CZ Espoo, FI Budapest, HU Oslo, NO Belgrade, RS see more	Locations Chuo City, JP HQ Guangzhou Shi, CN Taizhou, CN Puteaux, FR Frankfurt Am Main, DE Singapore, SG see more	Locations Cambridge, US HQ	Locations Stamford, US HQ Alcobendas, ES Boulder, US New York, US South San Francisco, US
Employees	Employees 1726% decrease	Employees 17,3684% decrease	Employees 7,778	Employees 20364% increase	Employees 65610% decrease
Valuation ($)	Valuation ($) 136.5 m	Valuation ($) N/A	Valuation ($) 78.7 b	Valuation ($) 250.8 m	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) $1.4m (FY, 2025)	Revenue (est.) N/A	Revenue (est.) ¥1.3t (FY, 2025)	Revenue (est.) $37.4m (FY, 2021)	Revenue (est.) N/A
Cost of goods	Cost of goods $1.4m (FY, 2025)	Cost of goods N/A	Cost of goods ¥363.7b (FY, 2025)	Cost of goods $10.5m (FY, 2021)	Cost of goods N/A
Gross profit	Gross profit $57.2k (FY, 2025)	Gross profit N/A	Gross profit ¥903.5b (FY, 2025)	Gross profit N/A	Gross profit N/A
Net income	Net income ($62.4m) (FY, 2025)	Net income N/A	Net income ¥434b (FY, 2025)	Net income ($251.1m) (FY, 2021)	Net income ($148.9m) (FY, 2017)
Funding
Total funding raised	Total funding raised N/A	Total funding raised N/A	Total funding raised N/A	Total funding raised $ 51.5m	Total funding raised $ 57m